The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

FDA approves Dupixent for treating bullous pemphigoid in adults, showing significant improvements in disease management.

A breakthrough treatment has allowed damaged retinal cells to regenerate themselves. The current research has been conducted on mice, but the pathways are the same in humans, which opens hope for ...

ICI-associated Bullous pemphigoid (irBP), a severe, blistering irCAE occurs in 0.3–1.5% of patients receiving ICI therapy. While systemic steroids can be effective, long courses may be required, which ...

(RTTNews) - Palatin Technologies, Inc. (PTNT), a biopharmaceutical company advancing melanocortin-based therapies, shared new preclinical findings at the 2025 ARVO Annual Meeting.

New research from Johns Hopkins Medicine suggests that low blood sugar may contribute to diabetic retinopathy and vision loss. The study identifies how hypoglycemia triggers damaging effects in ...

Low blood sugar contributes to eye damage and vision loss in diabetic retinopathy; experimental drug may help treat condition Date: May 6, 2025 Source: Johns Hopkins Medicine Summary: Scientists ...

Retinal health could also be affected by schizophrenia itself, for example through antipsychotic medication, lifestyle factors or diabetes. Extensive use of data from healthy individuals ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous adverse events, including bullous pemphigoid and lipodystrophy.

The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been accepted by the FDA for priority review, Sanofi announced in a press release ...

Diabetic retinopathy can lead to peripheral or nighttime vision loss, visual disturbances, and, if left untreated, blindness.